Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Cell Medica
Cell Medica
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Cell Medica appoints new CEO
Design & Build
Cell and Gene Therapy Catapult opens manufacturing centre
More than £60 million of UK government investment is being used to develop the new centre, which aims to accelerate growth of the industry in the UK
Recruitment
New CFO to lead Cell Medica financing
Research & Development
Cell Medica appoints CSO to accelerate R&D for CAR and TCR programmes
Media
Cell Medica acquires WT1 cancer immunotherapy from CGT Catapult
The acquisition transfers rights for WT1-TCR cell therapy from CGT Catapult to Cell Medica, also establishing development and manufacturing collaboration
Research & Development
Cell Medica and UCL to develop T cell receptor cancer products
Cell Medica gains an exclusive worldwide option and licensing agreement for these technologies
Pharmaceutical
Cell Medica begins commercial production at cell therapy facility in Germany
The first product has been manufactured and delivered to the patient
Subscribe now